San Mateo, CA, United States of America

Christine Tan

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 13(Granted Patents)


Location History:

  • San Mateo, CA (US) (2015 - 2021)
  • South San Francisco, CA (US) (2022)

Company Filing History:


Years Active: 2015-2022

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Christine Tan: Innovator in Antibody Therapeutics

Introduction

Christine Tan is a prominent inventor based in San Mateo, CA (US). She has made significant contributions to the field of antibody therapeutics, holding a total of 5 patents. Her work focuses on developing innovative solutions for treating inflammatory and oncological diseases.

Latest Patents

Among her latest patents is the invention titled "Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof." This invention provides anti-idiotypic antibodies against anti-PD-L1 antibodies and methods of using the same. Another notable patent is "Anti-PD-L1 antibodies and methods of use," which includes high affinity, humanized anti-PD-L1 monoclonal antibodies and related compositions. These antibodies can be utilized in various therapeutic methods for treating inflammatory and oncological diseases.

Career Highlights

Christine has worked with leading companies in the biotechnology sector, including Genentech, Inc. and Apexigen, Inc. Her experience in these organizations has allowed her to advance her research and contribute to the development of groundbreaking therapies.

Collaborations

Throughout her career, Christine has collaborated with esteemed colleagues, including Youjun Chen and William Mallet. These partnerships have further enriched her work and expanded the impact of her inventions.

Conclusion

Christine Tan is a trailblazer in the field of antibody therapeutics, with a strong portfolio of patents and a commitment to advancing medical science. Her innovative work continues to pave the way for new treatments in the fight against serious diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…